Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT03282617
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Cancer
Interventions
BIOLOGICAL:
CD137L-DC-EBV-VAX
Sponsor
National University Hospital, Singapore